Mercurialis annua: characterization of main allergens and cross-reactivity with other species

A Vallverdú1, P García-Ortega, J Martínez

  • 1IFIDESA-ARISTEGUI, Bilbao, Spain.

Insights

High sensitization to Mercurialis annua pollen affects nearly half of pollen-allergic patients in Spain. Key allergens identified are profilins, with low cross-reactivity to other common pollens.

Area of Science:

  • Allergy and Immunology
  • Plant Science
  • Biochemistry

Background:

  • Mercurialis annua (annual mercury) is a common plant in Spain.
  • Pollen sensitization to M. annua is a potential cause of allergic respiratory diseases.

Purpose of the Study:

  • To determine the prevalence of M. annua pollen sensitization in Spain.
  • To identify and characterize the major allergenic components of M. annua pollen.

Main Methods:

  • Multicentric study involving 420 pollen-allergic patients across six Spanish hospitals.
  • Skin prick tests (SPT) for M. annua sensitization.
  • SDS-PAGE immunoblotting and affinity chromatography for allergen identification.
  • In vitro techniques to assess cross-reactivity.

Main Results:

  • 46.4% of pollen-allergic patients showed positive SPT to M. annua.
  • Two major allergens, profilins (15.8 and 14.1 kD), were identified in 59% and 51% of sensitized individuals, respectively.
  • Low antigenic cross-reactivity was observed between M. annua and pollens from Olea europaea, Fraxinus elatior, Ricinus communis, Salsola kali, Parietaria judaica, and Artemisia vulgaris.

Conclusions:

  • M. annua pollen sensitization is highly prevalent in Spain.
  • Profilins are the primary allergens in M. annua pollen.
  • Cross-reactivity with other pollens is limited, suggesting M. annua as a specific allergen source.

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
28.7K
Allergic Reactions02:06

Allergic Reactions

Overview
26.3K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
206
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
278
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
266